Marker Therapeutics is a biotechnology company based in Saint Paul, MN that is dedicated to advancing novel T-cell therapies for blood cancers and solid tumors. Their multi-antigen targeted T cells are designed to recognize and kill multiple tumor targets without genetic modifications, leading to durable anti-tumor responses. With a focus on safety and efficacy, Marker Therapeutics has conducted several clinical trials and is currently evaluating their MultiTAA product candidates in various indications, including acute myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma, and breast cancer.
Driven by a passion for improving patients' lives, Marker Therapeutics' team of experts, including scientists and researchers, are committed to developing innovative cell therapy solutions. Their cutting-edge technology and approach have garnered positive results, paving the way for potential pivotal Phase 2 studies. With a strong emphasis on quality and patient outcomes, Marker Therapeutics is at the forefront of revolutionizing cancer treatment through their groundbreaking T-cell therapies.
Generated from the website